Eventide Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Eventide Asset Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-490,000	Closed	-$20M	–	197
2024 Q2	$20M	Hold	490,000	–	–	0.34%	91
2024 Q1	$20.7M	Hold	490,000	–	–	0.32%	92
2023 Q4	$20.8M	Hold	490,000	–	–	0.34%	88
2023 Q3	$10.7M	Hold	490,000	–	–	0.19%	120
2023 Q2	$15.6M	Buy	490,000 +178,000	+57%	+$5.46M	0.26%	100
2023 Q1	$7.61M	Buy	+312,000	New	+$9.16M	0.14%	121

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Eventide Asset Management's CERE Position: Q3 2024 in Review

Eventide Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 490,000 shares — an estimated $20M sold.

Eventide Asset Management first reported a position in CERE in Q1 2023 and held it in 6 quarters. The position peaked at $20.8M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Eventide Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Eventide Asset Management sold 490,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $20M.
Eventide Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
Eventide Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $20.8M in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Eventide Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.